Feasibility, Safety, and Preliminary Efficacy of Exercise During and After Neoadjuvant Rectal Cancer Treatment: A Phase II Randomized Controlled Trial
Clinical Colorectal Cancer · 2021-09 · 20 (3) · 216-226
DOI: 10.1016/j.clcc.2021.05.004 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical Colorectal Cancer, 2021-09. Verfasst von Andria R Morielli und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Kinesiology, Sport, and Recreation, University of Alberta, Edmonton, Alberta, Canada. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Rectal Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Canadian Institutes of Health Research, Canadian Cancer Society, Canada Research Chairs.
Abstract (Originalsprache)
BACKGROUND: Neoadjuvant chemoradiation (NACRT) improves outcomes for patients with rectal cancer; however, there are dose-limiting toxicities and only a 15% to 27% pathologic complete response (pCR) rate. Exercise may help manage toxicities and improve treatment response, but feasibility and early efficacy have not been established. EXERT was a phase II trial designed to establish the feasibility and safety of exercise and provide the first evidence of efficacy. MATERIALS AND METHODS: Patients with rectal cancer scheduled to receive NACRT were randomly assigned to usual care (n = 18) or exercise (n = 18) involving supervised exercise during NACRT and unsupervised exercise after NACRT. The primary outcome was cardiorespiratory fitness (VO2 peak). Clinical outcomes included treatment toxicities, treatment completion, and treatment response. RESULTS: Median attendance at supervised exercise sessions during NACRT was 82%, and median self-reported exercise after NACRT was 90 min/wk. From baseline to post-NACRT, VO2 peak increased by 0.4 mL·kg-1·min-1 in the exercise group and decreased by 0.8 mL·kg-1·min-1 in the usual care group (P = .47). There were no significant differences between groups for grade 3/4 toxicities or treatment completion. Of 18 patients in the exercise group, 10 (56%) achieved pCR/near pCR compared with 3 of 17 (18%) in the usual care group (P = .020). CONCLUSION: Exercise during and after NACRT is feasible for many patients with rectal cancer and may improve pCR despite limited fitness improvements. Larger trials are warranted to confirm if exercise is an effective intervention for improving treatment outcomes in this clinical setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Kinesiology, Sport, and Recreation, University of Alberta, Edmonton, Alberta, Canada.
- Department of Oncology, University of Alberta and Division of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada.
- Faculty of Kinesiology, Sport, and Recreation, University of Alberta, Edmonton, Alberta, Canada. Electronic address: kerry.courneya@ualberta.ca.
Förderung
- Canadian Institutes of Health Research
- Canadian Cancer Society
- Canada Research Chairs
Zitieren
APA
Morielli, A. R., Usmani, N., Boulé, N. G., Severin, D., Tankel, K., Joseph, K., Nijjar, T., Fairchild, A., & Courneya, K. S. (2021). Feasibility, Safety, and Preliminary Efficacy of Exercise During and After Neoadjuvant Rectal Cancer Treatment: A Phase II Randomized Controlled Trial. Clinical Colorectal Cancer, 20(3), 216-226. https://doi.org/10.1016/j.clcc.2021.05.004
Vancouver
Morielli AR, Usmani N, Boulé NG, Severin D, Tankel K, Joseph K, et al. Feasibility, Safety, and Preliminary Efficacy of Exercise During and After Neoadjuvant Rectal Cancer Treatment: A Phase II Randomized Controlled Trial. Clinical Colorectal Cancer. 2021;20(3):216-226. doi:10.1016/j.clcc.2021.05.004
BibTeX
@article{Morielli2021,
author = {Morielli, Andria R and Usmani, Nawaid and Boulé, Normand G and Severin, Diane and Tankel, Keith and Joseph, Kurian and Nijjar, Tirath and Fairchild, Alysa and Courneya, Kerry S},
title = {Feasibility, Safety, and Preliminary Efficacy of Exercise During and After Neoadjuvant Rectal Cancer Treatment: A Phase II Randomized Controlled Trial},
journal = {Clinical Colorectal Cancer},
year = {2021},
volume = {20},
number = {3},
pages = {216--226},
doi = {10.1016/j.clcc.2021.05.004}
}
EUVIMED